Image of a male athlete performing a jump with a blue sky on the background.

Going strong. Now going long.

IN.PACT™ Admiral™ XL Drug-Coated Balloon*
Contact us

WE'VE EXTENDED OUR DCB RANGE

Introducing new longer lengths to our IN.PACT™ Admiral™ Drug-Coated Balloon range, to give you more options for treatment of longer, complex lesions.

New 200 mm - 250 mm lengths now available

Learn more
Image of In.Pact Admiral XL 200mm and 250mm on a gradient navy blue background.
Illustration of DCBs showing the difference between using one long product instead of two standard sizes.

EXTRA LONG. EXTRA EFFICIENT.

Explore data
Save time illustration with clock icon and navy blue background.
Save cost illustration with calculator icon on a sky blue background.

CLINICAL PERFORMANCE   HIGHEST PRIMARY PATENCY1 91.1%2 MEAN LESION LENGTH 26 CM

5 YEARS GOING STRONG

IN.PACT™ Admiral™ DCB provides up to 180 days of drug release in the tissue3, delivering:

  • Highest patency benefit through 3 years4,‡
  • Lowest CD-TLR rates and lowest mortality through 5 years3,5
  • Most publications for a DCB§

Duration of drug in tissue

Data comes from different individual studies and may differ in a head-to-head comparison, and therefore may not be predictive of clinical results.

75% OF PATIENTS REINTERVENTION-FREE AT 5 YEARS4

Image of orange and blue people icons on a navy blue background.

technical specifications

Learn more
Image of an In.Pact Admiral XL on a gradient blue background.

see clinical data

Learn more

Request more information

Please fill in the form below.

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

*

The approved product name for the drug-coated balloon is IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter.

†

Primary patency not assessed after 3 years.

‡

Data on file UC202013694EE at Medtronic.

1

Based on clinical data for drug-coated balloons indicated to treat long SFA lesions (>180 mm): compared to Lutonix™* IFU BAW1387400r3. Per Stellarex™* IFU P011966-B, Stellarex is not indicated to treat lesions longer than 180 mm. Definitions of patency and lesion length may vary for different studies.

2

The IN.PACT Global Study Long Lesion Imaging Cohort D. Scheinert Circulation 2018.

3

IPA reference: PMA P140010: FDA Summary of Safety and Effectiveness Data

4

IN.PACT™ Admiral™ 5Y data: Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circ Cardiovasc Interv. June 2019;12(6):e007702.

5

Based on the mortality data from the LEVANT 2 IDE in the Lutonix™* DCB IFU (BAW1387400r6) and the IN.PACT™ SFA Trial in the IN.PACT™ Admiral™ DCB IFU (M052624T001). Gongora CA, Shibuya M, Wessler JD, et al. Impact of Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis. JACC Cardiovasc Interv. July 2015;8(8):1115-1123.

6

IPA reference: PMA P140010: FDA Summary of Safety and Effectiveness Data

7

Ranger Reference: PMA P190019: FDA Summary of Safety and Effectiveness Data

8

Lutonix Reference: Virmani R. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. 2014 Jan 1;83(1):132-40.

9

Stellarex reference: PMA P160049: FDA Summary of Safety and Effectiveness Data